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Abstract 45	
 46	
Introduction: Pharmacological salicylates are known to trigger respiratory exacerbations in 47	
patients with Non-Steroidal Exacerbated Respiratory Disease (N-ERD), a specific phenotype 48	
of Chronic Rhinosinusitis (CRS) and asthma. The impact of dietary sources of salicylates 49	
across subgroups of CRS is not well understood.  The hypothesis is that in patients with 50	
nasal polyps present, there is likely to be a higher incidence of symptom exacerbation due to 51	
dietary salicylates regardless of any known response to pharmacological salicylate. 52	
Methods: The Chronic Rhinosinusitis Epidemiology Study (CRES) was a questionnaire-53	
based case-control study which sought to characterise the UK CRS population in terms of 54	
sociological, economic and medical factors. Using specific questions to examine participant 55	
responses relating to symptom exacerbation from food groups thought to be high in 56	
salicylate content, this analysis of the CRES database sought to compare an estimate of the 57	
prevalence of dietary sensitivity due to food with higher potential salicylate content across 58	
patients with CRS with (CRSwNPs) and without nasal polyposis (CRSsNPs) and with allergic 59	
fungal rhinosinusitis (AFRS). 60	
Results: The CRSwNPs group were significantly more likely than controls to report 61	
symptom exacerbation due to ingestion of food groups with higher potential dietary salicylate 62	
content (OR 3.16, 95% CI 1.78 – 5.61, p<0.001). The same trend was observed amongst 63	
CRSsNPs participants to a lesser degree (OR 2.03, 95% CI 1.15 – 3.58, p=0.01). Reported 64	
response to the individual specific food groups wine, nuts, spicy foods, fruit and vegetables 65	
demonstrated that a statistically significant proportion of CRSwNPs and AFRS participants 66	
reported sensitivity to wine (Controls 0.9%, CRSwNPs 18.4%, AFRS 44.0%, p<0.008).  67	
Conclusions: This analysis suggests that there is an association between symptom 68	
exacerbation in response to food products with higher potential salicylate content, 69	
specifically wine, in CRS patients both with and without nasal polyposis when compared to 70	
		 3	
controls, but especially in the CRSwNPs and AFRS phenotypes.  Further studies are needed 71	
to detail if this relationship represents a causal relationship to dietary salicylate. The data 72	
present the possibility that a wider group of CRS patients may elicit salicylate sensitivity than 73	
those with known N-ERD.  74	
	75	
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Introduction 77	
Salicylic acid is a phenolic phytohormone found in plants, with roles in growth and 78	
development, photosynthesis, transpiration, ion uptake and transport. Salicylic acid also 79	
induces specific changes in leaf anatomy and chloroplast structure, and is involved in 80	
endogenous signaling, thereby mediating plant defence against pathogens 1. Salicylates are 81	
commonly found in a wide variety of foods, with unripe fruit and vegetables, spices, nuts and 82	
seeds thought to be particularly high in content. Assessments of daily consumption of 83	
salicylate vary, with a recent study in a Scottish population estimating daily intake to be 84	
4.42mg/day for males and 3.16mg/day for females 2. 85	
Formerly known as Samter’s Triad and AERD, Non-Steroidal Exacerbated Respiratory 86	
Disease (N-ERD) is characterised by the coexistence of asthma, eosinophilic rhinosinusitis 87	
and nasal polyposis, with respiratory exacerbations triggered by ingestion of aspirin 88	
(acetylsalicylic acid) or other non-steroidal anti-inflammatory medications (NSAIDs) 3, 4. N-89	
ERD forms a subgroup of asthma and/or chronic rhinosinusitis (CRS) which is often 90	
refractory to commonly used medical and surgical therapies. N-ERD is thought to affect 16% 91	
of patients with the subtype of CRS with nasal polyposis (CRSwNPs) 5. A low-salicylate diet 92	
has been touted as a possible adjunct in the management of patients with N-ERD 6. Whilst 93	
the impact of dietary salicylates in N-ERD is well recognised in the literature, little is known 94	
about the prevalence of dietary salicylate sensitivity across other phenotypes of CRS. The 95	
CRES dataset presented an opportunity to examine the prevalence of possible dietary 96	
salicylate sensitivity in all CRS patients regardless of their phenotype and any prior 97	
diagnosis of aspirin sensitivity. 98	
Objectives 99	
The Chronic Rhinosinusitis Epidemiology Study (CRES) was primarily designed to 100	
distinguish differences in socio-economic status, geography, medical/psychiatric co-101	
morbidity, lifestyle and overall quality of life between patients with CRS and healthy controls, 102	
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however patient-reported sensitivities to various foodstuffs were also captured as part of the 103	
study-specific questions. The specific aim of this analysis of the CRES database was to 104	
compare the prevalence of potential higher dietary salicylate sensitivity across CRS 105	
phenotypes (irrespective of prior diagnosis of N-ERD) and compared to controls and 106	
characterise any differences between them. This will help to inform ENT surgeons and 107	
respiratory physicians of the potential role of avoidance of dietary salicylates in CRS 108	
patients’ symptom control. 109	
Methods 110	
The study was sponsored by the University of East Anglia (UEA) and funded by the Anthony 111	
Long and Bernice Bibby Trusts. Ethical approval was granted by the Oxford C Research 112	
Ethics Committee (Ref: 07/H0606/100).  113	
Study Design 114	
The CRES was a prospective, questionnaire-based, case-control study conducted between 115	
October 2007 and September 2013 at 30 tertiary/secondary care sites across the United 116	
Kingdom. Patients with CRS and healthy control subjects were asked to complete a single, 117	
study-specific questionnaire, capturing a variety of demographic and socio-economic 118	
variables, environmental exposures and medical co-morbidities (See appendix 1).  119	
Participants and Data Sources 120	
Prospective participants were identified for recruitment at ENT outpatient clinics at 30 121	
participating centres. Patients with CRS were examined by a clinician and classified by 122	
subgroup of CRS (CRSwNPs, CRSsNPs or AFRS) as per EPOS criteria (see below). 123	
Healthy controls were recruited from family members of patients attending ENT clinic, and 124	
from members of hospital staff at recruitment sites.  125	
Questionnaires were completed during the clinic visit or taken home to be completed and 126	
returned by prepaid post. No participant identifiable data was captured therefore consent 127	
was not required by the ethics committee who stated that this was implied through return of 128	
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the questionnaire. Returned questionnaires were scanned and the data imported into in an 129	
electronic database in Microsoft Excel. Records in the database were compared to physical 130	
copies of the questionnaires by two members of the research team to ensure accuracy and 131	
consistency between the two.  132	
All CRS participants and healthy controls were required to meet the inclusion/exclusion 133	
outlined below: 134	
CRS	Participants	135	
Inc lusion Criter ia 136	
Criteria for diagnosis of CRS with or without polyps (EPOS guidelines)7 137	
At least two symptoms must be present for at least 12 weeks and include: 138	
• One of either nasal blockage/obstruction/congestion and/or nasal discharge 139	
(anterior/posterior nasal drip) 140	
• and either facial pain/pressure and/or reduction or loss of sense of smell 141	
and additionally: 142	
• endoscopic signs of: polyps and/or mucopurulent discharge primarily from middle 143	
meatus and/or; oedema/mucosal obstruction primarily in middle meatus 144	
• and/or CT changes: mucosal changes within the ostiomeatal complex and/or sinuses 145	
Patients were then classified as having chronic rhinosinusitis without polyps (CRSsNPs), 146	
chronic rhinosinusitis with nasal polyps (CRSwNPs) or allergic fungal rhinosinusitis (AFRS); 147	
patients with the latter additionally adhered to either the Bent and Kuhn criteria8 or the 148	
modified Vancouver criteria 9. 149	
 150	
Healthy	Control	Participants		151	
Exclusion Criter ia  152	
• Prior history of recurrent acute or chronic rhinosinusitis other than having had 153	
previous common colds (acute viral rhinosinusitis). 154	
• Any other nose/sinus disorders e.g allergic rhinitis (hayfever). 155	
• Active medical problems that have required a hospital visit within the last 12 months. 156	
Exclusion Criter ia  for  Both Groups 157	
• Patients/controls unable to comprehend written English. 158	
• Patients/controls under the age of 18 years. 159	
 160	
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Quantitative Variables and Bias 161	
Dietary questions were added as an amendment to the original questionnaire in 2012 on 162	
recognition of the need to ask specific questions related to diet. Questions exploring 163	
potential dietary salicylate sensitivity asked “Have you ever experienced any allergy 164	
symptoms such as wheezing, runny nose, or itchy skin when taking any of the following?” 165	
with a simple Yes/No checkbox for the response. The question was intentionally phrased to 166	
focus on respiratory/nasal exacerbations characterised by itching, wheezing and 167	
rhinorrhoea, in order that those with common gastrointestinal intolerance would not answer 168	
“yes” for the purposes of this questionnaire. Food groups included in the questionnaire were 169	
chosen to cover a broad range of foods believed to have a high level of salicylate content 170	
(table 1). Participants reporting a “yes” to any of the dietary questions were therefore 171	
considered to have self-reported exacerbation of symptoms in response to foods of potential 172	
high salicylate content. 173	
At the top of the list of food items, aspirin was also listed as an option to consider. For 174	
participants who also reported sensitivity to aspirin and also reported asthma as well as 175	
being diagnosed with CRSwNPs, were considered to have N-ERD for the purpose of this 176	
analysis; a more detailed analysis of asthma, N-ERD and inhalant allergy is reported 177	
elsewhere10. 178	
Sample Size Calculation 179	
Since this is a secondary analysis of an existing database, a power calculation was not 180	
performed for this specific analysis. The sample size calculation was based on the primary 181	
outcome of the study which was to look for common associations between socioeconomic 182	
factors and CRS. In order for the study to have 80% power to detect a difference of 10% in 183	
“low social class” between controls and CRS participants, assuming a 30% rate in the CRS 184	
participants, with approximately 5 CRS participants to 1 control patient, 965 CRS 185	
participants and 193 controls were required 11. 186	
		 8	
Statistical Methods  187	
All statistical analyses were conducted using IBM SPSS statistics v22. Proportions of CRS 188	
sub-groups reporting sensitivities to different food groups were compared by Chi-squared 189	
test or Fisher’s exact test where appropriate. A Bonferroni correction was applied to correct 190	
for multiple testing (0.05/6) (6 main groups of foods), resulting in p<0.008 being considered 191	
statistically significant. Odds ratios were calculated for main food groups and individual food 192	
groups by binary logistic regression and adjusted for potential confounding variables. For the 193	
purposes of regression, the AFRS group was merged with the CRSwNPs group due to the 194	
small sample size of the former. 195	
Results  196	
Study Partic ipants 197	
A total of 1535 questionnaires were returned with 1470 considered eligible for inclusion after 198	
removal of duplicates and questionnaires with missing data (see figure 1). However, 199	
questions relating to diet and allergy were added part way through the recruitment period. 200	
This analysis is therefore based on the 873 participants who completed the updated version 201	
of the questionnaire that included the dietary questions.  The overall response rate of those 202	
identified to take part in the study was 66% of those distributed for the entire study. 203	
Descriptive Data 204	
Of the 873 participants, 402 (46.0%) were CRSwNPs, 336 (38.5%) CRSsNPs, 25 (2.9%) 205	
AFRS and 110 (12.6%) controls. The demographic characteristics of each group are 206	
demonstrated in table 2. Controls were generally younger than CRS participants and had a 207	
greater proportion of females. Cases and controls were broadly similar in having a majority 208	
proportion of White British participants. The CRSwNPs and AFRS groups had a greater 209	
proportion of participants with asthma (52.5% and 68.0% respectively) and sensitivity to 210	
aspirin (10.4% and 44.0%). 9.9% (40 participants) of the CRSwNPs group and 40% (10 211	
participants) of the AFRS group reported both asthma and sensitivity to aspirin as defined 212	
above. Amongst this subset of participants with concurrent asthma and aspirin sensitivity, a 213	
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comparable proportion of the CRSwNPs group and AFRS group also reported sensitivity to 214	
one or more of the food groups (65.0% and 60% respectively – see figure 2). 215	
Primary Outcome Data and Main Results 216	
Participants with nasal polyps (including both those with CRSwNPs and AFRS) were most 217	
likely to report symptom exacerbation to one or more of the food groups included in the 218	
questionnaire when compared with controls. However, a breakdown of the analysis to 219	
specific food groups determined that of all possible paired combinations of controls, 220	
CRSwNPs and AFRS showed statistically significant variation in the proportion of 221	
participants reporting sensitivity to wine (Controls 0.9%, CRSwNPs 18.4%, AFRS 44.0%, 222	
p<0.001), as demonstrated in figure 3.  Participants with AFRS also reported significantly 223	
more reactions to nuts than controls (16.0% vs 0%, p=0.001).   Although several other pairs 224	
were found to be significant at the p<0.05 level (Fruit; Controls vs CRSwNPs p=0.04, 225	
Controls vs AFRS p=0.02, Vegetables; Controls vs AFRS p=0.03, CRSwNPs vs AFRS 226	
p=0.01, CRSsNPs vs AFRS p=0.04), these associations were not found to be statistically 227	
significant after the Bonferroni correction was applied.  228	
After adjusting for potential confounders including age, sex, and aspirin sensitivity, the 229	
association between foods with higher potential dietary salicylate and symptom exacerbation 230	
was enhanced (adjusted OR 3.16, 95% CI 1.78 – 5.61, p<0.001), as demonstrated in table 231	
3; the adjustment accounted for differences in the subgroup demographics 11. The CRSsNPs 232	
group were also found to be more likely to report sensitivity than controls (adjusted OR 2.03, 233	
95% CI 1.15 – 3.58, p=0.01), although to a lesser degree than the group with nasal 234	
polyposis. Separately, 56% (n=14) of the AFRS group reported symptom exacerbation, 235	
although this group was not included individually in the regression analysis due to the small 236	
sample size of 25 participants. A further analysis to remove participants who reported 237	
autoimmune disorders, ciliary dyskinesias and immunodeficiencies, did not change the 238	
associations reported above (table 3a). 239	
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Discussion 240	
The Chronic Rhinosinusitis Epidemiology Study is the largest epidemiological study of CRS 241	
in the UK to date and is believed to be the first study to collect data on patient reported 242	
symptom exacerbation in response to ingestion of foods with higher potential salicylate 243	
content in CRS subtypes other than the N-ERD subgroup. Other studies investigating 244	
sensitivity to foodstuffs in CRS subgroups have focused on non-specific food sensitisation 245	
and delayed food hypersensitivity measured by skin prick testing12, 13. 246	
Key Results 247	
Within the CRES population we observed a significantly increased risk of reported symptom 248	
exacerbation to wine in CRS participants both with and without nasal polyps when compared 249	
to controls. The CRSwNPs group were 3 times more likely than controls to report these 250	
responses. This likely reflects the inclusion of AFRS subjects in the test group and the fact 251	
that almost 10% of the CRSwNPs group fulfilled the criteria for N-ERD. The proportion of 252	
CRSwNPs participants suspected to have N-ERD in our study is lower than the 16% 253	
observed by Stevens et al in a US population and may be a result of methodological 254	
differences between the studies5. 255	
The fact that the prevalence of reported symptom exacerbation to food products containing 256	
potentially higher levels of salicylate is higher than patient reported aspirin sensitivity 257	
amongst CRS participants in our study could suggest that some participants may also be 258	
sensitive to aspirin but are unaware, although this relationship could be confounded by 259	
respiratory sensitivity to other dietary components which commonly cause respiratory 260	
symptoms such as sulphites14, which is true of wine where the biggest effect was seen. 261	
Potential symptoms arising from sulphite ingestion includes dermatitis, urticaria, flushing, 262	
hypotension, abdominal pain, diarrhoea, exacerbation of asthma and anaphylaxis. Sulphite 263	
sensitivity is reported to be prevalent in 3 to 10% of asthmatic subjects who ingest them14. 264	
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In the CRES qualitative sub-study, Erskine et al determined that dietary factors were 265	
frequently perceived to be a trigger for respiratory exacerbations, with wine being a specific 266	
trigger highlighted by one participant15. Esmaeilzadeh et al used an oral food challenge test 267	
in patients with CRSwNPs and found 69.9% of patients to be salicylate sensitive16. 268	
Interestingly they reported red grape to be one of the most common foods inducing a 269	
reaction. Our finding that CRS participants frequently reported sensitivity to wine also 270	
suggests that grapes are a common trigger of sensitivity, but it is very possible that in some 271	
participants this may be an effect of alcohol and/or sulphites as discussed above. There is 272	
recent evidence to show the effect of alcohol on symptom exacerbation in CRSwNPs was 273	
significantly more prevalent in patients suffering from recurrent disease and in patients with 274	
severe symptomatology17. 275	
Unlike aspirin sensitivity in the setting of N-ERD which is the result of abnormal arachidonic 276	
acid metabolism causing inhibition of cyclooxygenase-1 (COX-1) and a subsequent 277	
imbalance of inflammatory mediators18, non-acetylated salicylates of dietary origin have 278	
been shown to selectively inhibit cyclooxygenase-2 (COX-2) gene expression19. COX-2 is 279	
known to be down-regulated in the nasal polyps of patients with N-ERD20-22. It is therefore 280	
hypothesised that in addition to reactions to aspirin and other NSAIDs, patients with N-ERD 281	
are also likely to experience sensitivity to dietary sources of salicylates. Interestingly the 282	
CRSsNPs group in our study also demonstrated an increased risk of dietary salicylate 283	
sensitivity compared to controls. This likely points to the fact that current 284	
classification/phenotypic divisions of CRS do not necessarily reflect pathophysiological 285	
subgroups for which true endotypes are yet to be fully determined.  286	
Our data also appears to highlight an overlap between N-ERD and AFRS aetiopathogenic 287	
factors, as over half of AFRS participants appear to report symptom exacerbation. Whilst the 288	
small size of the AFRS group included in this study renders it difficult to draw definitive 289	
conclusions, the fact that similar proportions of participants in the AFRS and CRSwNPs 290	
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groups with concurrent asthma and aspirin sensitivity (thereby suggestive of N-ERD) also 291	
report symptom exacerbation to dietary salicylates, suggests there may be some 292	
commonality between the two groups. We suggest that N-ERD should be considered in all 293	
CRS patients who report symptom exacerbation in response to ingestion of food products 294	
with higher potential dietary salicylate content, the implications being identification of a more 295	
severe disease endotype, with early involvement of respiratory physicians where 296	
appropriate. If indeed there is overlap between the pathophysiological disease mechanisms 297	
of N-ERD and AFRS, aspirin desensitisation may be a potentially therapeutic option for the 298	
latter; but at the very least, patients can be advised to avoid wine and possibly nuts in order 299	
to prevent symptom exacerbations. 300	
Interpretation 301	
The interaction between diet and CRS is complex and poorly understood. A number of 302	
special diets including a low salicylate diet have a theoretical basis for being able to 303	
modulate the chronic inflammation seen in CRS, but the evidence for the clinical application 304	
of dietary adjustment in management is lacking and is not recommended in national 305	
guidelines23. In a small randomized control crossover trial of 10 N-ERD patients, Sommer et 306	
al investigated the use of the low salicylate diet as a management option in N-ERD and 307	
observed an improvement in both subjective and objective outcome measures in patients 308	
following the diet for a 6-week period6. The feasibility of implementing such a strategy as a 309	
treatment adjunct was questioned in a recent update on the management of N-ERD which 310	
highlighted the problem of long term adherence to the diet given the large number of 311	
commonly eaten foods containing salicylates24. 312	
Limitations 313	
Our results should be interpreted in the context of the limitations of the questionnaire-based 314	
design of the study. Whilst positive responses to questions regarding reactions to foods 315	
thought to be high in dietary salicylates are suggestive of potential symptom exacerbation, 316	
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only objective allergy testing or provocation tests could conclusively determine if this is the 317	
case25 and itchy skin in isolation is not a CRS symptom; some asthmatics also avoid 318	
NSAIDs on advice from their GP and need a provocation test for confirmation. The self-319	
reported nature of the respiratory sensitivity also renders the subject to recall bias, however 320	
other studies have used a similar means of capturing data17. Despite this, the potential error 321	
in recall should be equal across CRS subgroups and controls and therefore should not 322	
overly bias the results in any one subgroup. Furthermore, this study focused on a limited 323	
number of broad food groups thought to represent foods of moderate to high salicylate 324	
content. Future studies using validated food diaries and objective allergy testing are 325	
warranted to further investigate the potential role of dietary salicylate in CRS symptom 326	
exacerbation. 327	
Another limitation is the over-reporting of food sensitivities by the general population. About 328	
1-2% of the population have a medically diagnosed food allergy/sensitivity and yet 13% 329	
claim to have one26. In our controls 19% said they had a sensitivity, therefore it is possible 330	
that the real level of food sensitivity in our groups will probably be much lower than what they 331	
self-report. Table 1 also demonstrates the variability in the reported levels of salicylate in 332	
food, making categorisation of “high salicylate” foods somewhat problematic. 333	
General isabi l ity 334	
Studies of the potential role of dietary salicylates in CRS, such as our study and that carried 335	
out by Sommer et al, are hindered by the lack of consensus on the salicylate content of 336	
foodstuffs as demonstrated in table 1. The inconsistency in the literature is thought to be the 337	
result of methodological variation, along with differences in the variety, growing conditions 338	
and preparation of foods analysed27. Further basic science studies are required in order for 339	
accurate diet-based studies into the role of dietary salicylates in clinical conditions such as 340	
CRS to be carried out in the future.   341	
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Conclusion 342	
This analysis suggests that there is an association between symptom exacerbation in 343	
response to food products with higher potential salicylate content, specifically wine, in CRS 344	
patients both with and without nasal polyposis when compared to controls, but especially in 345	
the CRSwNPs and AFRS phenotypes.  Further studies are needed to detail the relationship 346	
between dietary intake and CRS subgroups and to determine if this apparent airway 347	
sensitivity is specifically a salicylate effect and moreover as to the reality of meaningful 348	
dietary modifications. The data present the possibility that a wider group of CRS patients 349	
may elicit salicylate sensitivity than those with known N-ERD.  350	
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Table 1. Salicylate content of selected foods covered by questions included in the 
questionnaire. 
  
  
 
 
Salicylic Acid Content (mg/100g) 
Food groups 
Malakar 
et al 
2017 
Swain et 
al 1985 
 
Frequency of sensitivity in CRES n 
(%) 
Control CRSs
NPs 
CRSw
NPs 
AFRS 
Spicy 
Foods 
      19 (17.3) 72 
(21.4) 
85 
(21.1) 
4 (16) 
  Chilli Powder - 1.3     
  Curry Powder - 218     
  Mustard Powder - 26     
  Paprika - 203     
  Red Chilli 
Peppers 
0.657 1.2     
  Cumin Powder 60.497 45     
  Black Pepper 4.57 6.2     
Wine*        1 (0.9) 29 
(8.6) 
74 
(18.4) 
11 (44.0) 
  White Wine - 0.1     
  Red Wine - 0.9     
  Champagne - 1.02     
Drinks*       2 (1.8) 14 
(4.2) 
18 
(4.2) 
0 (0.0) 
  Tea (English 
Breakfast) 
0.24 3     
  Coffee (instant 0.204 0.59     
		 18	
Caffeinated) 
  Drinking 
Chocolate 
5.148 -     
  Coca-cola - 0.25     
Nuts       0 (0.0) 12 
(3.6) 
17 
(4.2) 
4 (16.0) 
  Almonds 4.709 3     
  Peanuts - 1.12     
  Cashews 4.11 0.07     
Fruit       1 (0.9) 14 
(4.2) 
26 
(6.5) 
3 (12.0) 
  Grapes (white) 0.83 -     
  Sultana - 1.88     
  Dried dates 3.69 4.5     
  Nectarine 1.328 0.49     
  Peach 0.33 0.58     
  Apple (Granny 
Smith) 
0.97 0.59     
  Raspberry 1.052 3.14     
Vegeta
bles 
      0 (0.0) 3 (0.9) 2 (0.5) 2 (8.0) 
  Broccoli 1.101 0.65     
  Green Beans 1.388 0.11     
  Garden Peas 2.552 0.004     
  Tinned Tomato 0.642 0.53     
  Spinach 0.229 0.58     
  Sweet Potato 2.115 0.48     
*Values reported as 
mg/100ml. 
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Table 2. Demographics and selected health characteristics of study population. 
Characteristic Controls (n=110) CRSwNPs (n=402) CRSsNPs (n=336) AFRS (n=25) 
Age (years) (SD in 
brackets) 
44 (± 14.9) 55 (± 14.9) 51 (± 15.5) 57 (±14.1) 
Female n (%) 71 (64.5) 119 (29.6) 159 (47.3) 15 (60.0) 
White British n (%) 95 (86.4) 297 (73.9) 235 (69.9) 22 (88.0) 
          
Asthma n (%) 5 (4.5) 211 (52.5) 73 (21.7) 17 (68.0) 
Aspirin Sensitivity n  
(%) 
1 (0.9) 42 (10.4) 10 (3.0) 11 (44.0) 
Both above n (%) 0 (0) 40 (9.9) 4 (1.2)  10 (40) 
Missing data excluded. 
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Table 3. Association between CRS subtype and dietary salicylate sensitivity. The results demonstrate the association in participants who reported 
sensitivity to one or more of the sub groups of foods. 
Group Total (n) Dietary Salicylate Sensitivity (%) Crude OR 95% CI p value Adjusted OR* 95% CI p value 
Controls 110 21 (19.1) 1.00     1.00     
CRSwNPs 402 150 (37.3) 2.52 1.50 - 4.23 <0.001 2.56 1.39 - 4.71 0.002 
CRSsNPs 336 103 (30.7) 1.87 1.10  -  3.18 0.020 1.86 1.05 - 3.30 0.034 
AFRS 25 14 (56.0) 5.39 2.15 - 13.56 <0.001 3.84 1.36 - 10.86 0.011 
*Odds ratio adjusted for age, sex, asthma and aspirin sensitivity. 
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Table 3a. Association between CRS subtype and dietary salicylate sensitivity. The results demonstrate the association in participants who reported 
sensitivity to one or more of the sub groups of foods excluding individuals who reported yes to having an autoimmune disorder, immunodeficiency or 
ciliary dysmotility. 
 
 
Group Total (n) Dietary Salicylate Sensitivity (%) Crude OR 95% CI p value Adjusted OR* 95% CI p value 
Controls 109 21 (19.3) 1   1   
CRSwNPs 379 139 (36.7) 1.70 0.99 – 2.90 0.054 1.78 1.00 – 3.19 0.051 
CRSsNPs 302 87 (28.8) 2.43 1.44 – 4.08 0.001 2.59 1.40 – 4.80 0.003 
AFRS 23 14 (60.9) 6.52 2.49 – 17.08 <0.001 4.90 1.64 –14.63 0.004 
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Figure Legends: 
Figure 1. Participant flow diagram 
Figure 2. Proportion of participants in each group reporting asthma and aspirin sensitivity, and sensitivity to one or more salicylate containing 
food groups. CRSwNPs = Chronic Rhinosinusitis with nasal polyps; CRSsNPs = Chronic Rhinosinusitis without nasal polyps; AFRS = Allergic 
Fungal Rhinosinusitis. 
Fig. 3. Proportion of control group and CRS subgroups reporting sensitivity/symptom exacerbation.  *Pairs statistically significant at p<0.008 
(Bonferroni correction). CRSwNPs = Chronic Rhinosinusitis with nasal polyps; CRSsNPs = Chronic Rhinosinusitis without nasal polyps; AFRS 
= Allergic Fungal Rhinosinusitis. 
 
Appendix 1: Study questionnaire 
 







